Symbols / COCP $1.08 +0.00%
COCP Chart
About
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.88M |
| Enterprise Value | 8.74M | Income | -9.67M | Sales | — |
| Book/sh | 0.59 | Cash/sh | 0.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 11 | IPO | — |
| P/E | — | Forward P/E | -1.31 | PEG | — |
| P/S | — | P/B | 1.84 | P/C | — |
| EV/EBITDA | -0.90 | EV/Sales | — | Quick Ratio | 5.42 |
| Current Ratio | 5.78 | Debt/Eq | 20.64 | LT Debt/Eq | — |
| EPS (ttm) | -0.93 | EPS next Y | -0.83 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 08:00 | ROA | -45.77% |
| ROE | -94.94% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 13.78M |
| Shs Float | 9.12M | Short Float | 2.32% | Short Ratio | 4.31 |
| Short Interest | — | 52W High | 2.67 | 52W Low | 0.86 |
| Beta | 1.22 | Avg Volume | 70.85K | Volume | 23.39K |
| Target Price | $6.67 | Recom | None | Prev Close | $1.08 |
| Price | $1.08 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.67
Mean price target
2. Current target
$1.06
Latest analyst target
3. DCF / Fair value
$-7.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.06
Low
$6.00
High
$8.00
Mean
$6.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-20 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-01-03 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-10-04 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-06-02 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-05-24 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-01-24 | main | HC Wainwright & Co. | — → Buy | $35 |
| 2022-11-07 | main | HC Wainwright & Co. | — → Buy | $42 |
- Cocrystal Pharma (COCP) reports death of board director Japour - Stock Titan Fri, 13 Mar 2026 20
- Cocrystal Pharma Announces Passing of Board Member Japour - TipRanks Fri, 13 Mar 2026 21
- Cocrystal Pharma, Inc. to Present Clinical Progress Update at NobleCon 21 Conference - Quiver Quantitative Mon, 01 Dec 2025 08
- First norovirus antiviral trial takes on $60B global cost - Stock Titan Mon, 09 Mar 2026 12
- Tuesday’s Insider Activity: Major Buys at CBC, COCP; Sells at ARES, RKLB - Investing.com South Africa Wed, 26 Nov 2025 08
- Cocrystal Pharma, Inc. Closes $4.7 Million Registered Direct Offering with Additional $8.3 Million Potential from Warrants | COCP Stock News - Quiver Quantitative Mon, 15 Sep 2025 07
- Cocrystal Pharma (COCP) Reports Promising Results with Influenza Inhibitor | COCP Stock News - GuruFocus hu, 29 May 2025 07
- CDI-988 norovirus challenge trial begins at Cocrystal Pharma (NASDAQ: COCP) - Stock Titan Mon, 09 Mar 2026 12
- Insider Confidence Surges as Cocrystal Pharma Director Makes Bold Move - TipRanks Wed, 25 Feb 2026 08
- Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation - Yahoo Finance Fri, 18 Oct 2024 07
- Trust linked to Phillip Frost adds 20K Cocrystal (COCP) shares - Stock Titan Wed, 25 Feb 2026 08
- Cocrystal Pharma Stock Price Forecast. Should You Buy COCP? - StockInvest.us ue, 01 Dec 2020 15
- First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment - GlobeNewswire Mon, 09 Mar 2026 12
- COCP Stock Price and Chart — NASDAQ:COCP - TradingView Wed, 14 Mar 2018 04
- Human trial of first oral drug to fight norovirus cleared at Emory - Stock Titan hu, 18 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 20000 | 19952 | — | Purchase at price 1.00 per share. | FROST PHILLIP MD ET AL | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-24 00:00:00 | I |
| 1 | 50000 | 47280 | — | Purchase at price 0.95 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-06 00:00:00 | I |
| 2 | 50000 | 47275 | — | Purchase at price 0.95 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-31 00:00:00 | I |
| 3 | 20000 | 19310 | — | Purchase at price 0.97 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-30 00:00:00 | I |
| 4 | 65000 | 63202 | — | Purchase at price 0.97 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-26 00:00:00 | I |
| 5 | 4000 | 3975 | — | Purchase at price 0.99 - 1.00 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-26 00:00:00 | I |
| 6 | 20000 | 18812 | — | Purchase at price 0.94 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-25 00:00:00 | I |
| 7 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | PFENNIGER RICHARD C JR | Director | — | 2025-10-28 00:00:00 | D |
| 8 | 3598 | 4138 | — | Stock Award(Grant) at price 1.15 per share. | MARTIN JAMES J. CPA | Chief Executive Officer | — | 2025-10-28 00:00:00 | D |
| 9 | 359713 | 413670 | — | Stock Award(Grant) at price 1.15 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-28 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -17.27M | -23.69M | 2.95M | -13.84M |
| TotalUnusualItems | -163.00K | 2.54M | -20.70M | 40.00K |
| TotalUnusualItemsExcludingGoodwill | -163.00K | 2.54M | -20.70M | 40.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.50M | -17.98M | -38.84M | -14.19M |
| ReconciledDepreciation | 446.00K | -1.39M | 388.00K | 382.00K |
| EBITDA | -17.43M | -21.16M | -17.75M | -13.80M |
| EBIT | -17.88M | -21.16M | -18.14M | -14.18M |
| NetInterestIncome | 537.00K | 640.00K | -2.00K | -4.00K |
| InterestExpense | 2.00K | 4.00K | ||
| NormalizedIncome | -17.34M | -20.52M | -18.14M | -14.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.50M | -17.98M | -38.84M | -14.19M |
| TotalExpenses | 17.88M | 21.16M | 18.14M | 14.22M |
| TotalOperatingIncomeAsReported | -17.88M | -18.56M | -38.83M | -14.22M |
| DilutedAverageShares | 10.17M | 9.65M | 8.14M | 7.36M |
| BasicAverageShares | 10.17M | 9.65M | 8.14M | 7.36M |
| DilutedEPS | -1.72 | -1.87 | -4.77 | -0.16 |
| BasicEPS | -1.72 | -1.87 | -4.77 | -0.16 |
| DilutedNIAvailtoComStockholders | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncomeCommonStockholders | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncome | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncomeIncludingNoncontrollingInterests | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncomeContinuousOperations | -17.50M | -17.98M | -38.84M | -14.19M |
| PretaxIncome | -17.50M | -17.98M | -38.84M | -14.19M |
| OtherIncomeExpense | -163.00K | 2.54M | -20.70M | 40.00K |
| SpecialIncomeCharges | 0.00 | 2.60M | -20.69M | 0.00 |
| OtherSpecialCharges | -2.60M | 1.60M | ||
| ImpairmentOfCapitalAssets | 0.00 | 19.09M | 0.00 | |
| GainOnSaleOfSecurity | -163.00K | -65.00K | -6.00K | 40.00K |
| NetNonOperatingInterestIncomeExpense | 537.00K | 640.00K | -2.00K | -4.00K |
| TotalOtherFinanceCost | -537.00K | -640.00K | 2.00K | |
| InterestExpenseNonOperating | 2.00K | 4.00K | ||
| OperatingIncome | -17.88M | -21.16M | -18.14M | -14.22M |
| OperatingExpense | 17.88M | 21.16M | 18.14M | 14.22M |
| ResearchAndDevelopment | 12.54M | 15.17M | 12.39M | 8.79M |
| SellingGeneralAndAdministration | 5.34M | 5.99M | 5.75M | 5.43M |
| GeneralAndAdministrativeExpense | 5.34M | 5.99M | 5.75M | 5.43M |
| OtherGandA | 5.34M | 5.99M | 5.75M | 5.43M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 10.17M | 10.17M | 8.14M | 8.12M |
| ShareIssued | 10.17M | 10.17M | 8.14M | 8.12M |
| TotalDebt | 1.81M | 1.85M | 297.00K | 534.00K |
| TangibleBookValue | 9.52M | 26.38M | 39.57M | 58.46M |
| InvestedCapital | 9.52M | 26.38M | 39.57M | 77.55M |
| WorkingCapital | 9.15M | 25.83M | 38.96M | 57.78M |
| NetTangibleAssets | 9.52M | 26.38M | 39.57M | 58.46M |
| CapitalLeaseObligations | 1.81M | 1.85M | 297.00K | 534.00K |
| CommonStockEquity | 9.52M | 26.38M | 39.57M | 77.55M |
| TotalCapitalization | 9.52M | 26.38M | 39.57M | 77.55M |
| TotalEquityGrossMinorityInterest | 9.52M | 26.38M | 39.57M | 77.55M |
| StockholdersEquity | 9.52M | 26.38M | 39.57M | 77.55M |
| RetainedEarnings | -333.42M | -315.91M | -297.93M | -259.09M |
| AdditionalPaidInCapital | 342.93M | 342.29M | 337.49M | 336.63M |
| CapitalStock | 10.00K | 10.00K | 8.00K | 8.00K |
| CommonStock | 10.00K | 10.00K | 8.00K | 8.00K |
| TotalLiabilitiesNetMinorityInterest | 3.93M | 4.88M | 1.27M | 1.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.50M | 1.61M | 57.00K | 298.00K |
| LongTermDebtAndCapitalLeaseObligation | 1.50M | 1.61M | 57.00K | 298.00K |
| LongTermCapitalLeaseObligation | 1.50M | 1.61M | 57.00K | 298.00K |
| CurrentLiabilities | 2.43M | 3.26M | 1.22M | 1.54M |
| OtherCurrentLiabilities | 12.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 301.00K | 240.00K | 240.00K | 236.00K |
| CurrentCapitalLeaseObligation | 301.00K | 240.00K | 240.00K | 236.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 117.00K | 109.00K | 130.00K | 104.00K |
| PayablesAndAccruedExpenses | 2.01M | 2.91M | 846.00K | 1.19M |
| CurrentAccruedExpenses | 468.00K | 1.69M | 232.00K | 615.00K |
| Payables | 1.54M | 1.22M | 614.00K | 578.00K |
| AccountsPayable | 1.54M | 1.22M | 614.00K | 578.00K |
| TotalAssets | 13.46M | 31.26M | 40.84M | 79.39M |
| TotalNonCurrentAssets | 1.88M | 2.17M | 662.00K | 20.07M |
| NonCurrentPrepaidAssets | 29.00K | 46.00K | 46.00K | 46.00K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 19.09M | ||
| Goodwill | 0.00 | 19.09M | ||
| NetPPE | 1.85M | 2.12M | 616.00K | 931.00K |
| AccumulatedDepreciation | -1.93M | -1.80M | -1.61M | -1.43M |
| GrossPPE | 3.78M | 3.92M | 2.23M | 2.36M |
| OtherProperties | 3.62M | 3.77M | 2.10M | 2.23M |
| MachineryFurnitureEquipment | 155.00K | 155.00K | 131.00K | 131.00K |
| CurrentAssets | 11.58M | 29.09M | 40.18M | 59.32M |
| OtherCurrentAssets | 430.00K | 1.77M | 2.24M | 568.00K |
| RestrictedCash | 75.00K | 75.00K | 75.00K | 50.00K |
| PrepaidAssets | 568.00K | |||
| Receivables | 1.22M | 890.00K | 716.00K | 0.00 |
| TaxesReceivable | 1.22M | 890.00K | 716.00K | 0.00 |
| AccountsReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 9.86M | 26.35M | 37.14M | 58.70M |
| CashAndCashEquivalents | 9.86M | 26.35M | 37.14M | 58.70M |
| CashFinancial | 9.86M | 26.35M | 37.14M | 58.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.49M | -14.78M | -21.51M | -12.77M |
| RepaymentOfDebt | 0.00 | -7.00K | -27.00K | -39.00K |
| IssuanceOfCapitalStock | 0.00 | 4.00M | 0.00 | 38.51M |
| CapitalExpenditure | -8.00K | -118.00K | -74.00K | -52.00K |
| EndCashPosition | 9.94M | 26.43M | 37.22M | 58.76M |
| BeginningCashPosition | 26.43M | 37.22M | 58.76M | 33.06M |
| ChangesInCash | -16.49M | -10.79M | -21.54M | 25.70M |
| FinancingCashFlow | 0.00 | 3.99M | -27.00K | 38.47M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 3.99M | -27.00K | 38.47M |
| NetCommonStockIssuance | 0.00 | 4.00M | 0.00 | 38.51M |
| CommonStockIssuance | 0.00 | 4.00M | 0.00 | 38.51M |
| NetIssuancePaymentsOfDebt | 0.00 | -7.00K | -27.00K | -39.00K |
| NetLongTermDebtIssuance | 0.00 | -7.00K | -27.00K | -39.00K |
| LongTermDebtPayments | 0.00 | -7.00K | -27.00K | -39.00K |
| InvestingCashFlow | -8.00K | -118.00K | -74.00K | -52.00K |
| CashFlowFromContinuingInvestingActivities | -8.00K | -118.00K | -74.00K | -52.00K |
| NetPPEPurchaseAndSale | -8.00K | -118.00K | -74.00K | -52.00K |
| PurchaseOfPPE | -8.00K | -118.00K | -74.00K | -52.00K |
| OperatingCashFlow | -16.48M | -14.67M | -21.43M | -12.72M |
| CashFlowFromContinuingOperatingActivities | -16.48M | -14.67M | -21.43M | -13.15M |
| ChangeInWorkingCapital | 140.00K | 2.34M | -2.71M | 170.00K |
| ChangeInOtherCurrentAssets | 192.00K | |||
| ChangeInPayablesAndAccruedExpense | -895.00K | 2.05M | -321.00K | -217.00K |
| ChangeInPrepaidAssets | 1.36M | 470.00K | -1.68M | -169.00K |
| ChangeInReceivables | -325.00K | -174.00K | -716.00K | 556.00K |
| ChangesInAccountReceivables | 0.00 | 556.00K | ||
| OtherNonCashItems | -210.00K | 1.56M | -209.00K | 239.00K |
| StockBasedCompensation | 643.00K | 801.00K | 855.00K | 724.00K |
| AssetImpairmentCharge | 0.00 | 19.09M | 0.00 | |
| DepreciationAmortizationDepletion | 446.00K | -1.39M | 388.00K | 382.00K |
| DepreciationAndAmortization | 446.00K | -1.39M | 388.00K | 382.00K |
| Depreciation | 446.00K | -1.39M | 388.00K | 382.00K |
| OperatingGainsLosses | -12.00K | -49.00K | ||
| GainLossOnInvestmentSecurities | -12.00K | -49.00K | ||
| NetIncomeFromContinuingOperations | -17.50M | -17.98M | -38.84M | -14.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for COCP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|